Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charmi Patel

Showing results (21-30 of 69) with videos related to

Pageof 7
Sort By:
Journal of Managed Care & Specialty Pharmacy|September 20, 2022
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) studyAnirban Basu, Carmela Benson, Ibrahim Turkoz, et al.
Journal of Medical Economics|October 20, 2021
Economic burden to commercial payers of young adults with schizophrenia in ColoradoJacqueline Pesa, Charmi Patel, David Rotter, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 31, 2023
Optimizing Computer-Aided Diagnosis with Cost-Aware Deep Learning ModelsCharmi Patel, Yiyang Wang, Thiruvarangan Ramaraj, et al.
Journal of Managed Care & Specialty Pharmacy|December 24, 2021
Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims DatabaseJacqueline Pesa, David Rotter, Eros Papademetriou, et al.
Current Medical Research and Opinion|March 30, 2018
A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozinLawrence Blonde, Charmi Patel, Brahim Bookhart, et al.
JAMA Network Open|September 15, 2023
Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With SchizophreniaPengxiang Li, Carmela Benson, Zhi Geng, et al.
Advances in Therapy|August 10, 2019
Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective AnalysisCharmi Patel, Antoine El Khoury, Ahong Huang, et al.
Journal of Managed Care & Specialty Pharmacy|January 24, 2023
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophreniaAnirban Basu, Charmi Patel, Alex Z Fu, et al.
Journal of Medical Economics|March 24, 2023
Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United StatesPengxiang Li, Carmela Benson, Zhi Geng, et al.
Psychiatric Services (Washington, D.C.)|November 14, 2023
Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With SchizophreniaJalpa A Doshi, Pengxiang Li, Zhi Geng, et al.
Pageof 7

Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
Journal of Managed Care & Specialty Pharmacy|September 20, 2022
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) studyAnirban Basu, Carmela Benson, Ibrahim Turkoz, et al.
Journal of Medical Economics|October 20, 2021
Economic burden to commercial payers of young adults with schizophrenia in ColoradoJacqueline Pesa, Charmi Patel, David Rotter, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 31, 2023
Optimizing Computer-Aided Diagnosis with Cost-Aware Deep Learning ModelsCharmi Patel, Yiyang Wang, Thiruvarangan Ramaraj, et al.
Journal of Managed Care & Specialty Pharmacy|December 24, 2021
Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims DatabaseJacqueline Pesa, David Rotter, Eros Papademetriou, et al.
Current Medical Research and Opinion|March 30, 2018
A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozinLawrence Blonde, Charmi Patel, Brahim Bookhart, et al.
JAMA Network Open|September 15, 2023
Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With SchizophreniaPengxiang Li, Carmela Benson, Zhi Geng, et al.
Advances in Therapy|August 10, 2019
Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective AnalysisCharmi Patel, Antoine El Khoury, Ahong Huang, et al.
Journal of Managed Care & Specialty Pharmacy|January 24, 2023
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophreniaAnirban Basu, Charmi Patel, Alex Z Fu, et al.
Journal of Medical Economics|March 24, 2023
Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United StatesPengxiang Li, Carmela Benson, Zhi Geng, et al.
Psychiatric Services (Washington, D.C.)|November 14, 2023
Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With SchizophreniaJalpa A Doshi, Pengxiang Li, Zhi Geng, et al.
Pageof 7